Concepedia

Author

Bin Meng

Tianjin Medical University Cancer Institute and Hospital

Also Known As

B Meng, B. Meng, BIN MENG, Bao-Wei Meng, Baosen Meng, BeiBei Meng, Beibei Meng, Bin Meng, Bingbing Meng, Ge Hu

123

Publications

2K

Citations

24

H-Index

29

Concepts

All Affiliations

Tianjin Medical University Cancer Institute and HospitalSun Yat-sen UniversityUniversity of Nebraska Medical CenterCentral South UniversityFudan University
BM

About

Bin Meng is an author at Tianjin Medical University Cancer Institute and Hospital specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

257

2

Cell Biology

3

3

158

3

Immunology

3

3

158

4

Health Sciences

1

1

117

5

Molecular Medicine

1

1

117

Bin Meng

×

35

Publications

1.5K

Citations

23

H-Index

YearCitations

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas

Longyun Chen, Mattias Berglund, Weicheng Ren,

Blood

2016

199

Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma

Weicheng Ren, Xiaofei Ye, Hong Su,

Blood

2018

141

Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

Xin Huang, Bin Meng, Javeed Iqbal,

Journal of Clinical Oncology

2013

120

NEK2 induces autophagy‐mediated bortezomib resistance by stabilizing Beclin‐1 in multiple myeloma

Jiliang Xia, Yanjuan He, Bin Meng,

Molecular Oncology

2020

117

A Dual-targeting Anticancer Approach: Soil and Seed Principle

Junjie Li, Ziping Sun, Jian Zhang,

Radiology

2011

86

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

Ling Dong, Huijuan Lv, Wei Li,

Oncotarget

2016

64

Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma

Xuan Wu, Jiliang Xia, Jingyu Zhang,

British Journal of Haematology

2020

62

Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)

Xiaobin Shang, Gang Zhao, Fei Liang,

Annals of Translational Medicine

2022

59

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL

Tingting Zhang, Hengqi Liu, Lei Jiao,

Journal for ImmunoTherapy of Cancer

2022

57

Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)

Xiaobin Shang, Wencheng Zhang, Gang Zhao,

Frontiers in Oncology

2022

56

Page 1